Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,741 to 1,760 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cancer-Associated Fibroblasts Hinder Lung Squamous Cell Carcinoma Oxidative Stress-Induced Apoptosis via METTL3 Mediated m6A Methylation of COL10A1. | Oxid Med Cell Longev | 2022 | 36246404 | PubTator, text mining | PubMed |
| m6A-Related Angiogenic Genes to Construct Prognostic Signature, Reveal Immune and Oxidative Stress Landscape, and Screen Drugs in Hepatocellular Carcinoma. | Oxid Med Cell Longev | 2022 | 36246403 | PubTator, text mining | PubMed |
| News from around the RNA world: new avenues in RNA biology, biotechnology and therapeutics from the 2022 SIBBM meeting. | Biol Open | 2022 | 36239357 | PubTator, text mining | PubMed |
| Insights into Exosome in the Intervertebral Disc: Emerging Role for Disc Homeostasis and Normal Function. | Int J Med Sci | 2022 | 36237988 | PubTator, text mining | PubMed |
| Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma. | Transl Cancer Res | 2022 | 36237271 | PubTator, text mining | PubMed |
| Decreased Urine N6-methyladenosine level is closely associated with the presence of diabetic nephropathy in type 2 diabetes mellitus. | Front Endocrinol (Lausanne) | 2022 | 36237191 | PubTator, text mining | PubMed |
| Potential of Kalanchoe pinnata as a Cancer Treatment Adjuvant and an Epigenetic Regulator. | Molecules | 2022 | 36234962 | PubTator, text mining | PubMed |
| The Epitranscriptomic Mechanism of Metal Toxicity and Carcinogenesis. | Int J Mol Sci | 2022 | 36233132 | PubTator, text mining | PubMed |
| Role of m6A RNA Methylation in Thyroid Cancer Cell Lines. | Int J Mol Sci | 2022 | 36232810 | PubTator, text mining | PubMed |
| Integrated Analyses of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pan-Cancer. | Int J Mol Sci | 2022 | 36232485 | PubTator, text mining | PubMed |
| m6A Modification of Long Non-Coding RNA HNF1A-AS1 Facilitates Cell Cycle Progression in Colorectal Cancer via IGF2BP2-Mediated CCND1 mRNA Stabilization. | Cells | 2022 | 36230970 | PubTator, text mining | PubMed |
| Exploration of N6-Methyladenosine Profiles of mRNAs and the Function of METTL3 in Atherosclerosis. | Cells | 2022 | 36230944 | PubTator, text mining | PubMed |
| Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2022 | 36230580 | PubTator, text mining | PubMed |
| Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma. | Front Genet | 2022 | 36226185 | PubTator, text mining | PubMed |
| The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development. | Front Oncol | 2022 | 36226062 | PubTator, text mining | PubMed |
| N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas. | Explor Target Antitumor Ther | 2022 | 36226036 | PubTator, text mining | PubMed |
| The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface. | Front Immunol | 2022 | 36225914 | PubTator, text mining | PubMed |
| Epigenetic regulation of B cells and its role in autoimmune pathogenesis. | Cell Mol Immunol | 2022 | 36220996 | PubTator, text mining | PubMed |
| Oncofetal protein IGF2BP1 regulates IQGAP3 expression to maintain stem cell potential in cancer. | iScience | 2022 | 36217548 | PubTator, text mining | PubMed |
| Leucine zipper protein 2 serves as a prognostic biomarker for prostate cancer correlating with immune infiltration and epigenetic regulation. | Heliyon | 2022 | 36217461 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=88